|
Differential expression of human cyclin G1 (CCNG1) in cancer: A novel biomarker in development for CCNG1 inhibitor therapy. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Caris Life Sciences; NantHealth |
Leadership - Caris Life Sciences; NantHealth |
Stock and Other Ownership Interests - Caris Life Sciences; NantHealth |
|
Patents, Royalties, Other Intellectual Property - Patent WO/2016/141169; Patent WO/2016/141169 |
|
|
|
Stock and Other Ownership Interests - NantWorks; OncoPlex Diagnostics; Qiagen |
Research Funding - NantWorks |
Patents, Royalties, Other Intellectual Property - For a biomarker signature for response to treatment in lung cancer. |
Travel, Accommodations, Expenses - NantWorks |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma |
Consulting or Advisory Role - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma |
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma |
Research Funding - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Counterpoint Biomedica |
Patents, Royalties, Other Intellectual Property - University of Southern California |